Dalia Rotstein

When to consider an escalation approach for MS treatment 2:12
When to consider an escalation approach for MS treatment
Dalia Rotstein • 27 Oct 2022
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD 2:50
Chronic cognitive impairment improved after eculizumab initiation in cases of NMOSD
Dalia Rotstein • 25 Feb 2022
Is EBV the main cause of MS onset? 2:28
Is EBV the main cause of MS onset?
Dalia Rotstein • 25 Feb 2022
Prognostic factors in NMOSD: age, ethnicity, and relapse history 2:07
Prognostic factors in NMOSD: age, ethnicity, and relapse history
Dalia Rotstein • 8 Oct 2021
Key research questions in seronegative NMOSD 1:30
Key research questions in seronegative NMOSD
Dalia Rotstein • 8 Oct 2021
Identifying risk factors for AQP4+ NMOSD 3:18
Identifying risk factors for AQP4+ NMOSD
Dalia Rotstein • 8 Oct 2021
The predictive value of NEDA-3 for long-term disability in MS 4:03
The predictive value of NEDA-3 for long-term disability in MS
Dalia Rotstein • 8 Oct 2021
Improving educational opportunities for neurology residents globally 1:17
Improving educational opportunities for neurology residents globally
Dalia Rotstein • 16 Feb 2021
The impact of social networks on physical impairment in MS 1:34
The impact of social networks on physical impairment in MS
Dalia Rotstein • 16 Feb 2021
No evidence of disease activity as a predictive measure of long-term disability in RRMS 2:51
No evidence of disease activity as a predictive measure of long-term disability in RRMS
Dalia Rotstein • 16 Feb 2021
What to look out for at ACTRIMS 2021 2:17
What to look out for at ACTRIMS 2021
Dalia Rotstein • 16 Feb 2021
The content of VJNeurology is intended for healthcare professionals